Myriad receives reimbursement for the BRACAnalysis Diagnostic System in Japan

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Myriad Genetics has received reimbursement and launched the BRACAnalysis Diagnostic System in Japan to help physicians determine which people affected with breast and ovarian cancer have hereditary breast and ovarian cancer syndrome and qualify for additional diagnostic and medical management.

BRACAnalysis was approved by Japan’s Ministry of Health, Labour and Welfare in November 2019 for this indication.

Table of Contents

YOU MAY BE INTERESTED IN

As the debate around Galleri, the multi-cancer detection test developed by GRAIL Inc., rages on, fueled most recently by the full-steam-ahead support it has received from regulatory and legislative bodies, NCI Director Anthony Letai has turned his attention to the available data.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login